Ads
related to: pd l1 cancer- Clinical Study Results
View Clinical Study Results
& Efficacy Info For IMFINZI.
- Request Representative
Fill Out A Brief Form To Request
Assistance From A Representative.
- Recommended Dosing
Determine The Appropriate Dosing
For A Patient On IMFINZI.
- Download Resources
Find IMFINZI Dosing Brochures, FAQs
& More In The Resource Library.
- Nurse Website
Discover Resources For
Nurses About IMFINZI.
- Physician Resources
Find Programs & Support Resources
To Share With Your IMFINZI Patients
- Clinical Study Results
Search results
Results From The WOW.Com Content Network
PD-L1 is shown to be highly expressed in a variety of malignancies, particularly lung cancer. In order to anticipate the effectiveness of gene therapy or systemic immunotherapy in blocking the PD-1 and PD-L1 checkpoints, PD-L1 might be employed as a prognostic marker and a target for anti-cancer immunity.
In the cancer disease state, the interaction of PD-L1 on the tumor cells with PD-1 on a T-cell reduces T-cell function signals to prevent the immune system from attacking the tumor cells. [9] Use of an inhibitor that blocks the interaction of PD-L1 with the PD-1 receptor can prevent the cancer from evading the immune system in this way. [ 9 ]
PD-L1 on the cell surface binds to PD-1 on an immune cell surface, which inhibits immune cell activity. Among PD-L1 functions is a key regulatory role on T cell activities. [3] [4] It appears that (cancer-mediated) upregulation of PD-L1 on the cell surface may inhibit T cells that might otherwise attack. Antibodies that bind to either PD-1 or ...
Programmed cell death protein 1 (PD-1), (CD279 cluster of differentiation 279). PD-1 is a protein encoded in humans by the PDCD1 gene. [5] [6] PD-1 is a cell surface receptor on T cells and B cells that has a role in regulating the immune system's response to the cells of the human body by down-regulating the immune system and promoting self-tolerance by suppressing T cell inflammatory activity.
Among PD-L1 functions is a key regulatory role on T cell activities. It appears that (cancer-mediated) upregulation of PD-L1 on the cell surface may inhibit T cells that might otherwise attack. PD-L1 on cancer cells also inhibits FAS- and interferon-dependent apoptosis, protecting cells from cytotoxic molecules produced by T cells.
The company is going after an important target: non-small cell lung cancer (NSCLC). ... Merck's Keytruda, in treating patients with first-line NSCLC with a PD-L1 protein overexpression.
Ads
related to: pd l1 cancer